Motilium (Domperidone)

Domperidone, the active ingredient in Motilium, is a dopamine D2 receptor antagonist presented as an oral tablet for oral use. It is used to relieve nausea, vomiting and to improve gastric motility in conditions such as gastroparesis and functional dyspepsia. GNH USA supplies Motilium as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Motilium acts on the gastrointestinal tract and the central vomiting centre to reduce symptoms of nausea and improve motility. - Nausea: reduces the sensation of nausea and the urge to vomit. - Vomiting: helps prevent episodes of vomiting associated with various triggers. - Gastroparesis: enhances gastric emptying in patients with delayed stomach emptying. - Functional dyspepsia: alleviates upper abdominal discomfort and early satiety. - Gastroesophageal reflux: supports reduction of reflux symptoms by improving gastric clearance.

Domperidone is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Dry mouth: reduced salivary flow causing a dry sensation. - Headache: mild to moderate head pain. - Abdominal cramps: discomfort or cramping in the stomach area. - Diarrhoea: loose stools occurring occasionally. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, potentially serious. - Extrapyramidal symptoms: rare movement disorders such as tremor. - Hyperprolactinaemia: elevated prolactin levels causing galactorrhoea. - Allergic reaction: rash, itching, swelling or difficulty breathing.

Before prescribing Domperidone, consider patient‑specific factors and safety measures. - Cardiac risk assessment: evaluate history of arrhythmia or prolonged QT interval. - Liver function: monitor in patients with hepatic impairment. - Drug‑induced prolactin elevation: be aware of potential hormonal effects. - Pregnancy and lactation: use only if clearly needed after risk‑benefit analysis. - Elderly patients: start with the lowest effective dose and monitor closely. - Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture.

Domperidone may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase domperidone plasma levels, raising cardiac risk. - QT‑prolonging agents (e.g., quinidine, haloperidol): additive effect on cardiac repolarisation.

Moderate Interactions (Monitor Closely):\n- Anticholinergic drugs: may enhance dry‑mouth and constipation. - Antiparkinsonian agents: possible reduction of therapeutic effect. - Other dopamine antagonists: increased risk of extrapyramidal symptoms.